Search Within

Population Sciences Research Program

  1. "Nursing"
  2. "Dermatology Service"
Formats
  1. Journal Article (12)
  2. Meeting Abstract (11)
Groups
  1. Department of Medicine (23)
  2. Dermatology (23)
  3. Dermatology Service (23)
  4. Division of Subspecialty Medicine (23)
  5. Nursing (23)
  6. Survivorship Research (17)

More Groups

People
  1. Patricia Myskowski (13)
  2. Steven Horwitz (12)
  3. Alison Moskowitz (11)
  4. Allan Halpern (9)
  5. Deborah Phelan (8)
  6. David Straus (6)

More People

Years
  1. 2023 (2)
  2. 2021 (4)
  3. 2017 (2)
  4. 2016 (2)
  5. 2015 (2)
  6. 2014 (1)

More Years

Publications
  1. Blood (5)
  2. Hematological Oncology (2)
  3. Journal of Clinical Oncology (2)
  4. Journal of Investigative Dermatology (2)
  5. American Journal of Hematology (1)
  6. American Journal of Preventive Medicine (1)

More Publications

Publishers
  1. American Society of Hematology (5)
  2. Elsevier Science, Inc. (3)
  3. Wiley Blackwell (3)
  4. American Association for Cancer Research (2)
  5. American Society of Clinical Oncology (2)
  6. A.J. Jannetti (1)

More Publishers

Results (23)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reduced dose brentuximab vedotin for mycosis fungoides appears to prolong response duration by balancing efficacy and tolerability
    Meeting Abstract

    Munayirji, B.; Khan, N.; Myskowski, P.; Geller, S.; Noor, S.; Kheterpal, M. K.; Davey, T.; Hancock, H.; Perez, L.; Miller, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients
    Journal Article

    Gu, S.; Menzer, C.; Hay, J. L.; Pena, C.; Dusza, S.; Lacouture, M. E.; Markova, A.
    Supportive Care in Cancer (2023)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Clinical outcome and prognosis of young patients with mycosis fungoides
    Journal Article

    Virmani, P.; Levin, L.; Myskowski, P. L.; Flores, E.; Marchetti, M. A.; Skripnik Lucas, A.; Pulitzer, M.; Horwitz, S.; Trippett, T.; Moskowitz, A.; more...
    Pediatric Dermatology (2017)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Long-term follow-up and management of small and medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferations of acral sites: A multicenter experience
    Journal Article

    Virmani, P.; Jawed, S.; Myskowski, P. L.; Horwitz, S.; Skripnik Lucas, A.; Moskowitz, A.; Pulitzer, M.; Zain, J.; Rosen, S. T.; Querfeld, C.
    International Journal of Dermatology (2016)

    Fulltext@MSK | Save